We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TECH's Q1 adjusted EPS rose 4.8% to 44 cents, beating estimates by 10%, while revenues grew 5% to $299.7M.
TECH's Protein Sciences revenues climbed 9% to $219.7M, while Diagnostics and Spatial Biology grew 1%.
Bio-Techne shareholders approved the Merck KGaA merger, with closing expected by late 2026 or early 2027.
Bio-Techne Corporation (TECH - Free Report) reported adjusted earnings per share (EPS) of 44 cents for the first quarter of fiscal 2027, up 4.8% year over year. The figure surpassed the Zacks Consensus Estimate by 10%.
The quarter's adjustments excluded amortization of intangible assets, acquisition-related expenses, stock-based compensation, restructuring costs and certain litigation charges, among others. GAAP EPS was 18 cents compared with 24 cents in the prior-year quarter.
TECH's Revenues in Detail
Net sales totaled $299.7 million, up 5% year over year on a reported basis and 7% on an organic basis. The figure surpassed the Zacks Consensus Estimate by 2.3%. Foreign currency had an immaterial impact, while a business held for sale had an unfavorable impact of 2%.
Consumables revenues increased 2.4% year over year to $237.3 million, while instrument revenues rose 16.8% to $25.5 million. Services revenues declined 18.3% to $22.5 million. Royalty revenues surged to $14.5 million from $5.6 million in the year-ago period.
Bio-Techne's Protein Sciences Sales Rise
Within Protein Sciences, Bio-Techne recorded revenues of $219.7 million, up 9% year over year from $202.2 million. Organic revenues also increased 9%, while foreign currency had an immaterial impact.
The segment's operating margin contracted 50 basis points (bps) to 37.9% from 38.4% in the prior-year quarter. Segment operating income increased to $83.2 million from $77.7 million a year ago, reflecting higher sales despite the narrower margin.
TECH's Diagnostics and Spatial Biology Performance
Within Diagnostics and Spatial Biology, revenues totaled $80.2 million, increasing 1% year over year from $79.5 million. Organic revenues also grew 1%, with foreign currency having an immaterial impact.
The segment's operating margin contracted 380 bps to 7.4% from 11.2% in the prior-year quarter. Segment operating income declined to $5.9 million from $8.9 million, reflecting weaker profitability despite modest revenue growth.
In June 2026, Merck KGaA, Darmstadt, Germany, entered into a definitive agreement to acquire Bio-Techne Corporation for $73 per share in cash. The transaction values Bio-Techne at an enterprise value of approximately $11.3 billion, representing a 36% premium to its one-month volume-weighted average trading price. The acquisition is subject to customary closing conditions.
The deal brings together two complementary life sciences companies, strengthening their ability to serve customers across the entire life sciences value chain, from discovery and translational research to development, testing and commercial manufacturing. The merger is expected to strengthen its global presence and create a more connected organization across North America, Europe and Asia-Pacific, while providing employees with greater opportunities for collaboration and professional development.
Per the latest update, Bio-Techne shareholders approved and adopted the merger agreement with Merck KGaA at a special shareholders' meeting, marking an important step toward completing the acquisition. The transaction is expected to be closed by late 2026 or early 2027, subject to the satisfaction of customary closing conditions.
Our Take
Bio-Techne exited the fiscal first quarter with better-than-expected results, wherein both earnings and revenues beat estimates. Both the business segments posted revenue growth.
Instead of issuing a traditional earnings press release, the company disclosed its quarterly results in its Form 10-Q filing.
Zacks Rank & Other Stocks to Consider
TECH currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace (MEDP - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 at present, posted third-quarter 2026 adjusted EPS of $3.00, exceeding the Zacks Consensus Estimate by 14.94%. Revenues of $3.05 billion topped the Zacks Consensus Estimate by 5.84%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an earnings yield of 2.5% against the industry’s negative 2.1% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 15.12%.
Medpace, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $4.84, which surpassed the Zacks Consensus Estimate by 8.76%. Revenues of $716 million beat the Zacks Consensus Estimate by 1.02%.
MEDP has an estimated long-term earnings growth rate of 14.3% compared with the industry’s 13.2%. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 9.77%.
GE HealthCare, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $1.34, which topped the Zacks Consensus Estimate by 10.74%. Revenues of $5.51 billion beat the Zacks Consensus Estimate by 2.87%.
GEHC has an earnings yield of 6.5% compared with the industry’s 2.8%. The company beat earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.15%.
View the Zacks #1 Rank List
Image: Bigstock
TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances
Key Takeaways
Bio-Techne Corporation (TECH - Free Report) reported adjusted earnings per share (EPS) of 44 cents for the first quarter of fiscal 2027, up 4.8% year over year. The figure surpassed the Zacks Consensus Estimate by 10%.
The quarter's adjustments excluded amortization of intangible assets, acquisition-related expenses, stock-based compensation, restructuring costs and certain litigation charges, among others. GAAP EPS was 18 cents compared with 24 cents in the prior-year quarter.
TECH's Revenues in Detail
Net sales totaled $299.7 million, up 5% year over year on a reported basis and 7% on an organic basis. The figure surpassed the Zacks Consensus Estimate by 2.3%. Foreign currency had an immaterial impact, while a business held for sale had an unfavorable impact of 2%.
Consumables revenues increased 2.4% year over year to $237.3 million, while instrument revenues rose 16.8% to $25.5 million. Services revenues declined 18.3% to $22.5 million. Royalty revenues surged to $14.5 million from $5.6 million in the year-ago period.
Bio-Techne's Protein Sciences Sales Rise
Within Protein Sciences, Bio-Techne recorded revenues of $219.7 million, up 9% year over year from $202.2 million. Organic revenues also increased 9%, while foreign currency had an immaterial impact.
The segment's operating margin contracted 50 basis points (bps) to 37.9% from 38.4% in the prior-year quarter. Segment operating income increased to $83.2 million from $77.7 million a year ago, reflecting higher sales despite the narrower margin.
TECH's Diagnostics and Spatial Biology Performance
Within Diagnostics and Spatial Biology, revenues totaled $80.2 million, increasing 1% year over year from $79.5 million. Organic revenues also grew 1%, with foreign currency having an immaterial impact.
The segment's operating margin contracted 380 bps to 7.4% from 11.2% in the prior-year quarter. Segment operating income declined to $5.9 million from $8.9 million, reflecting weaker profitability despite modest revenue growth.
Bio-Techne Corp Price, Consensus and EPS Surprise
Bio-Techne Corp price-consensus-eps-surprise-chart | Bio-Techne Corp Quote
TECH's Expected Merger With Merck KGaA
In June 2026, Merck KGaA, Darmstadt, Germany, entered into a definitive agreement to acquire Bio-Techne Corporation for $73 per share in cash. The transaction values Bio-Techne at an enterprise value of approximately $11.3 billion, representing a 36% premium to its one-month volume-weighted average trading price. The acquisition is subject to customary closing conditions.
The deal brings together two complementary life sciences companies, strengthening their ability to serve customers across the entire life sciences value chain, from discovery and translational research to development, testing and commercial manufacturing. The merger is expected to strengthen its global presence and create a more connected organization across North America, Europe and Asia-Pacific, while providing employees with greater opportunities for collaboration and professional development.
Per the latest update, Bio-Techne shareholders approved and adopted the merger agreement with Merck KGaA at a special shareholders' meeting, marking an important step toward completing the acquisition. The transaction is expected to be closed by late 2026 or early 2027, subject to the satisfaction of customary closing conditions.
Our Take
Bio-Techne exited the fiscal first quarter with better-than-expected results, wherein both earnings and revenues beat estimates. Both the business segments posted revenue growth.
Instead of issuing a traditional earnings press release, the company disclosed its quarterly results in its Form 10-Q filing.
Zacks Rank & Other Stocks to Consider
TECH currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace (MEDP - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 at present, posted third-quarter 2026 adjusted EPS of $3.00, exceeding the Zacks Consensus Estimate by 14.94%. Revenues of $3.05 billion topped the Zacks Consensus Estimate by 5.84%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an earnings yield of 2.5% against the industry’s negative 2.1% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 15.12%.
Medpace, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $4.84, which surpassed the Zacks Consensus Estimate by 8.76%. Revenues of $716 million beat the Zacks Consensus Estimate by 1.02%.
MEDP has an estimated long-term earnings growth rate of 14.3% compared with the industry’s 13.2%. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 9.77%.
GE HealthCare, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $1.34, which topped the Zacks Consensus Estimate by 10.74%. Revenues of $5.51 billion beat the Zacks Consensus Estimate by 2.87%.
GEHC has an earnings yield of 6.5% compared with the industry’s 2.8%. The company beat earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.15%.